Astex Pharmaceuticals

UK - CambridgePharmaceutical1 H-1B visas (FY2023)

Focus: Astex Pharmaceuticals is a UK-based public company specializing in fragment-based drug discovery with a focus on oncology and hematologic malignancies. The company maintains an active pipeline of 30+ programs across Phase 1-3 development.

Neurology

Profile data last refreshed 15h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Astex Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Astex Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

5 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

multitargeted receptor tyrosine kinase inhibitor MP470

Lymphoma

N/A

Clinical Trials (1)

NCT00504205MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

N/A

Help build intelligence for Astex Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering fragment-based drug discovery platform offers rare expertise in a differentiated technology approach to oncology
Robust pipeline with 4 Phase 3 programs (rubitecan, guadecitabine, decitabine, pentostatin) provides multiple near-term catalysts and clinical validation opportunities
Established public company status with UK Cambridge location offers stability and access to top scientific talent in a biotech hub

Watch Out For

Zero active job openings listed signals potential hiring freeze, organizational restructuring, or operational challenges
Minimal recent H1B sponsorship (1 approval in 2023) and lack of visible hiring data suggest limited headcount expansion or recruitment activity
Heavy reliance on Phase 1-2 programs (15 of 20 trials) with only 4 Phase 3 candidates indicates prolonged clinical timelines before potential approvals and revenue impact

Generated by Claude from Astex Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ASTX660

Acute Myeloid Leukemia

Phase 1

Clinical Trials (3)

NCT04411030A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam

Phase 1

NCT04155580A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase 1

NCT04479800Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers

Phase 1

tolinapant

Head and Neck Squamous Cell Carcinoma

Phase 1

Clinical Trials (1)

NCT05245682Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer

Phase 1

cedazuridine

Myelodysplastic Syndrome

Phase 1

Clinical Trials (3)

NCT05007873ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Phase 2

NCT04953923Thorough QT Assessment of Cedazuridine in Healthy Subjects

Phase 1

NCT03875287Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Phase 1

TAS1553

Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT04637009A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

Phase 1

bisantrene

Acute Myeloid Leukemia

Phase 1

ASTX727 + Day 2 Food

Myelodysplastic Syndromes

Phase 1

Clinical Trials (1)

NCT03813186Effect of Food on Blood Levels of ASTX727

Phase 1

SGI-110

Metastatic Melanoma

Phase 1

Clinical Trials (1)

NCT02608437A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients

Phase 1

Talazoparib

Metastatic Breast Cancer

Phase 1

Clinical Trials (1)

NCT04134884Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Phase 1

MP-470 + topotecan

Malignant Disease

Phase 1

Clinical Trials (1)

NCT00881166Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

Phase 1

Inqovi

Clonal Cytopenia of Undetermined Significance

Phase 1

Clinical Trials (1)

NCT06802146Early Intervention in High Risk CCUS

Phase 1

ASTX727

Neurological Cancer

Phase 1

Clinical Trials (1)

NCT03922555ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Phase 1

Metastatic Colorectal Cancer

Phase 1

Clinical Trials (1)

NCT01966289SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)

Phase 1

9-nitrocamptothecin

Solid Tumors

Phase 1

Clinical Trials (1)

NCT00006047Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide

Phase 1

SGI-1776

Relapsed/Refractory Leukemias

Phase 1

Clinical Trials (2)

NCT01239108Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

Phase 1

NCT00848601Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

Phase 1

ASTX029

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04466514A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029

Phase 1

SGI-110 Dose Escalation

Previously Treated Metastatic Colorectal Cancer

Phase 1/2

Clinical Trials (1)

NCT01896856Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

Phase 1/2

ASTX727

MDS/MPN

Phase 1/2

Clinical Trials (1)

NCT04061421Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

Phase 1/2

AT13387

Non-small Cell Lung Cancer

Phase 2

Clinical Trials (4)

NCT01294202A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

Phase 2

NCT01712217A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Phase 1/2

NCT01685268A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Phase 1/2

+1 more

Cytoxan

Lymphoma

Phase 2

Clinical Trials (1)

NCT00496873Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

Phase 2

amuvatinib

Solid Tumors

Phase 2

Clinical Trials (2)

NCT01357395A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer

Phase 2

NCT00894894Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies

Phase 1

AT7519M

Multiple Myeloma

Phase 2

Clinical Trials (3)

NCT01627054A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia

Phase 2

NCT01652144A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma

Phase 2

NCT01183949Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

Phase 1/2

SGI-110

Hepatocellular Carcinoma

Phase 2

Clinical Trials (1)

NCT01752933SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Phase 2

SGI-110

Myeloproliferative Neoplasms

Phase 2

Clinical Trials (1)

NCT03075826A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

Phase 2

AT9283

Multiple Myeloma

Phase 2

Clinical Trials (3)

NCT01145989A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

NCT00522990Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

Phase 1/2

NCT00443976Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma

Phase 1

ASTX727

MDS

Phase 2

Clinical Trials (1)

NCT04857645ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

Phase 2

SGI-110

Ovarian Cancer

Phase 2

Clinical Trials (1)

NCT01696032SGI-110 in Combination With Carboplatin in Ovarian Cancer

Phase 2

decitabine/cedazuridine

Myelodysplastic Syndrome

Phase 3

Clinical Trials (4)

NCT06297629A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Phase 2

NCT05835011A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

Phase 2

NCT05360160A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Phase 1/2

+1 more

rubitecan

Pancreatic Cancer

Phase 3

Clinical Trials (5)

NCT00005871Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer

Phase 3

NCT00005870Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas

Phase 3

NCT00005869Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Phase 3

+2 more

pentostatin

Acute Graft Versus Host Disease

Phase 3

Clinical Trials (5)

NCT00254163Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients

Phase 3

NCT00541034Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 2

NCT00571662Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

Phase 2

+2 more

decitabine

Myelodysplastic Syndrome

Phase 3

Clinical Trials (5)

NCT00043381Decitabine Versus Supportive Care in Adults With Advanced-stage MDS

Phase 3

NCT03306264Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Phase 3

NCT00042016Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Phase 2

+2 more

guadecitabine

Myelodysplastic Syndrome

Phase 3

Clinical Trials (5)

NCT02348489SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

Phase 3

NCT02907359Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Phase 3

NCT02920008Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

Phase 3

+2 more

Nipent, Cytoxan, Rituxan

Chronic Lymphocytic Leukemia

Phase 4

Clinical Trials (1)

NCT00131313Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 76 clinical trials

Top TAs: Oncology, Hematology

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

63 pipeline

Hematology

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub